Nav: Home

A lifeline for leaky lung cells

December 02, 2019

About 80% of patients with heart failure develop pulmonary edema - the leakage of fluid out of the lungs' blood vessels and into the air-filled alveoli. This condition reduces the amount of oxygen that the lungs can absorb, which can prevent patients from doing everyday activities and even be fatal. There are no drugs currently available to directly treat the leakage once it starts; the most commonly prescribed medications simply lower blood pressure or the amount of fluid in the entire body in an attempt to reduce the damage.

Now, a project a decade in the making at the Wyss Institute for Biologically Inspired Engineering at Harvard University and Boston Children's Hospital (BCH) has identified a molecular pathway that could offer a way to target pulmonary edema itself with minimal side effects. The advance is based on engineering of adeno-associated virus (AAV) vectors as gene therapy delivery systems that target the lung and studies using primary human lung cells in a Lung Alveolus Chip. The research is reported in APL Bioengineering.

"Pulmonary edema is similar to a leak in a water pipe. The most effective thing to do is to plug the leak, but current drugs on the market work to shut off the water supply altogether and hope the leak fixes by itself," said first co-author Ratnakar Potla, Ph.D., M.B.B.S., a Research Fellow previously in the Vascular Biology program at BCH and now at the Wyss Institute. "With our method, we can actually target the leak, which is a much more efficient way to address the problem."

An off-target target

The team focused their investigation on a specific channel protein found in the membranes of lung cells that regulates the flow of substances between the lung's alveoli (air sacs) and blood vessels, called TRPV4. This channel is known to be activated by physical forces, such as the motion of breathing. Its mechanosensitivity can also cause a problem, however, in patients who have increased pressure in their lungs' blood vessels, often caused by a backup of fluid when the heart can no longer pump effectively. The physical strain imparted on TRPV4 activates it, causing the lung tissues to become more "leaky," which in turn puts more pressure on the surrounding blood vessels, causing a vicious feedback loop that worsens pulmonary edema.

Drugs have been developed to shut down TRPV4 chemically by blocking all channel activity, including a candidate from GlaxoSmithKline currently in a phase III clinical trial. But TRPV4 activity plays an important role in many other body processes, such as bone remodeling and bladder tone, so its complete inactivation can cause unwanted side effects and toxicities that limit the amount of drug that can be delivered.

To circumvent this problem, the Wyss and BCH researchers focused on a different membrane protein, CD98hc, which is responsible for transmitting mechanical forces to the TRPV4 channel. In separate studies, they found that the overexpression of a specific region of the CD98hc protein (the high homology, or HH domain) prevents mechanical activation of TRPV4, so the team hypothesized that a gene therapy delivering that region of the protein to lung cells could be an effective treatment for vascular leakage in the lung that leads to pulmonary edema.

To test that theory, they created gene therapy constructs using different serotypes of AAV as delivery vehicles containing the genetic sequence that codes for the HH domain of the CD98hc protein. They then tested how well the constructs delivered their cargo into the genomes of human pulmonary alveolar epithelial cells and human primary lung microvascular endothelial cells - the cell types that form the interface between air and liquid spaces in the lung. They identified AAV2.5T as the most promising serotype, as it could successfully infect and drive gene expression in both the epithelial and endothelial cells.

Crucially, the cells that overexpressed the HH domain of CD98hc displayed almost complete inhibition of mechanically-activated calcium signaling through TRPV4, while a drug that stimulates TRPV4 chemically could restore this calcium signaling response - evidence that the gene therapy blocked TRPV4's mechanical signaling pathway while leaving the rest of its functionality intact.

Plugging the leaks

The researchers then evaluated the effect of overexpression of the HH domain in a human Lung Alveolus Chip previously developed at the Wyss Institute as a clinically relevant model for a human lung. The microfluidic chip contains two parallel channels separated by a permeable membrane, one lined with primary human lung alveolar epithelial cells and perfused with air, and the other with human lung endothelial cells and perfused with liquid medium. To simulate the physical forces imparted on the cells by breathing motions, the chips are cyclically stretched and relaxed using suction. The team observed that when the chips' air channels were filled with fluid for four hours to simulate pulmonary edema, the barrier between the chips' air and liquid compartments was compromised, and the chips failed to recover even after the fluid was removed.

When they introduced their gene therapy vector into the chips, they saw that leakage was greatly reduced and the barrier strength of the lung cells remained intact, even when under physical strain mimicking breathing motions. "Remarkably, we saw a significant improvement in lung function even though only about 30% of the lung epithelial cells and 10% of the vascular endothelial cells were successfully transduced with the gene coding for the HH domain of CD98, indicating that this strategy is extremely protective," said co-author Rachelle Prantil-Baun, Ph.D., a Senior Staff Scientist at the Wyss Institute.

To determine how blocking the mechanical activation of TRPV4 provides this protective effect, the researchers analyzed the cells in the Lung Alveolus Chip using fluorescence imaging. They saw that submerging the air channel in fluid without the application of their gene therapy led to breaks in the cell-cell junctions that help maintain the integrity of the air-liquid barrier, while these junctions remained intact in cells treated with the gene therapy.

Interestingly, they also found that transfection with the HH domain changed the endothelial cells' behavior: whereas these cells usually rearrange themselves so that they are perpendicular to the direction of the physical force being applied to them, those with the AAV-delivered gene did not. As a result, the population of cells was more stable, preserving the cell-cell junctions and suggesting a mechanism by which leakiness is prevented. The hope is that these insights can be leveraged to develop specific mechanotherapeutic drugs for more targeted treatment of pulmonary edema in the future.

"This is one the first examples of how the mechanical signaling activity of a transmembrane molecule that is sensitive to both physical forces and chemical cues can be selectively targeted with a tailored mechanotherapeutic to provide a more specific therapeutic response. We hope there will be many more to follow," said corresponding author and Wyss Founding Director Donald Ingber, M.D., Ph.D., who is also the Judah Folkman Professor of Vascular Biology at Harvard Medical School (HMS) and the Vascular Biology Program at BCH, and Professor of Bioengineering at Harvard's John A. Paulson School of Engineering and Applied Sciences.
-end-
Additional authors of the paper include former Wyss Institute members Juan Li, Ph.D., Amy Wen, Ph.D., Ezekiel Benshirim, Ariel Seebarran, Olivier Henry, Ph.D., and Oren Levy, Ph.D., M.B.A.; current Wyss members Maximilian Benz and Sarah Gilpin, Ph.D.; and Benjamin Matthews, M.D. from Boston Children's Hospital and HMS. This research was supported by the National Institutes of Health.

Wyss Institute for Biologically Inspired Engineering at Harvard

Related Science Articles:

75 science societies urge the education department to base Title IX sexual harassment regulations on evidence and science
The American Educational Research Association (AERA) and the American Association for the Advancement of Science (AAAS) today led 75 scientific societies in submitting comments on the US Department of Education's proposed changes to Title IX regulations.
Science/Science Careers' survey ranks top biotech, biopharma, and pharma employers
The Science and Science Careers' 2018 annual Top Employers Survey polled employees in the biotechnology, biopharmaceutical, pharmaceutical, and related industries to determine the 20 best employers in these industries as well as their driving characteristics.
Science in the palm of your hand: How citizen science transforms passive learners
Citizen science projects can engage even children who previously were not interested in science.
Applied science may yield more translational research publications than basic science
While translational research can happen at any stage of the research process, a recent investigation of behavioral and social science research awards granted by the NIH between 2008 and 2014 revealed that applied science yielded a higher volume of translational research publications than basic science, according to a study published May 9, 2018 in the open-access journal PLOS ONE by Xueying Han from the Science and Technology Policy Institute, USA, and colleagues.
Prominent academics, including Salk's Thomas Albright, call for more science in forensic science
Six scientists who recently served on the National Commission on Forensic Science are calling on the scientific community at large to advocate for increased research and financial support of forensic science as well as the introduction of empirical testing requirements to ensure the validity of outcomes.
World Science Forum 2017 Jordan issues Science for Peace Declaration
On behalf of the coordinating organizations responsible for delivering the World Science Forum Jordan, the concluding Science for Peace Declaration issued at the Dead Sea represents a global call for action to science and society to build a future that promises greater equality, security and opportunity for all, and in which science plays an increasingly prominent role as an enabler of fair and sustainable development.
PETA science group promotes animal-free science at society of toxicology conference
The PETA International Science Consortium Ltd. is presenting two posters on animal-free methods for testing inhalation toxicity at the 56th annual Society of Toxicology (SOT) meeting March 12 to 16, 2017, in Baltimore, Maryland.
Citizen Science in the Digital Age: Rhetoric, Science and Public Engagement
James Wynn's timely investigation highlights scientific studies grounded in publicly gathered data and probes the rhetoric these studies employ.
Science/Science Careers' survey ranks top biotech, pharma, and biopharma employers
The Science and Science Careers' 2016 annual Top Employers Survey polled employees in the biotechnology, biopharmaceutical, pharmaceutical, and related industries to determine the 20 best employers in these industries as well as their driving characteristics.
Three natural science professors win TJ Park Science Fellowship
Professor Jung-Min Kee (Department of Chemistry, UNIST), Professor Kyudong Choi (Department of Mathematical Sciences, UNIST), and Professor Kwanpyo Kim (Department of Physics, UNIST) are the recipients of the Cheong-Am (TJ Park) Science Fellowship of the year 2016.
More Science News and Science Current Events

Top Science Podcasts

We have hand picked the top science podcasts of 2019.
Now Playing: TED Radio Hour

In & Out Of Love
We think of love as a mysterious, unknowable force. Something that happens to us. But what if we could control it? This hour, TED speakers on whether we can decide to fall in — and out of — love. Guests include writer Mandy Len Catron, biological anthropologist Helen Fisher, musician Dessa, One Love CEO Katie Hood, and psychologist Guy Winch.
Now Playing: Science for the People

#542 Climate Doomsday
Have you heard? Climate change. We did it. And it's bad. It's going to be worse. We are already suffering the effects of it in many ways. How should we TALK about the dangers we are facing, though? Should we get people good and scared? Or give them hope? Or both? Host Bethany Brookshire talks with David Wallace-Wells and Sheril Kirschenbaum to find out. This episode is hosted by Bethany Brookshire, science writer from Science News. Related links: Why Climate Disasters Might Not Boost Public Engagement on Climate Change on The New York Times by Andrew Revkin The other kind...
Now Playing: Radiolab

An Announcement from Radiolab